These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 35455959)

  • 1. Mass Spectrometry for Neurobiomarker Discovery: The Relevance of Post-Translational Modifications.
    Azevedo R; Jacquemin C; Villain N; Fenaille F; Lamari F; Becher F
    Cells; 2022 Apr; 11(8):. PubMed ID: 35455959
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alpha-synuclein post-translational modifications as potential biomarkers for Parkinson disease and other synucleinopathies.
    Schmid AW; Fauvet B; Moniatte M; Lashuel HA
    Mol Cell Proteomics; 2013 Dec; 12(12):3543-58. PubMed ID: 23966418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-translational modifications of pancreatic fluid proteins collected via the endoscopic pancreatic function test (ePFT).
    Paulo JA; Kadiyala V; Brizard S; Banks PA; Steen H; Conwell DL
    J Proteomics; 2013 Oct; 92():216-27. PubMed ID: 23500127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative Proteomics for the Evaluation of Protein Expression and Modifications in Neurodegenerative Diseases.
    Conti A; Alessio M
    Int Rev Neurobiol; 2015; 121():117-52. PubMed ID: 26315764
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterizing disease-associated changes in post-translational modifications by mass spectrometry.
    Thygesen C; Boll I; Finsen B; Modzel M; Larsen MR
    Expert Rev Proteomics; 2018 Mar; 15(3):245-258. PubMed ID: 29376447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detecting post-translational modification signatures as potential biomarkers in clinical mass spectrometry.
    Mnatsakanyan R; Shema G; Basik M; Batist G; Borchers CH; Sickmann A; Zahedi RP
    Expert Rev Proteomics; 2018 Jun; 15(6):515-535. PubMed ID: 29893147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of Post-translational Modifications in Alzheimer's Disease.
    Ramesh M; Gopinath P; Govindaraju T
    Chembiochem; 2020 Apr; 21(8):1052-1079. PubMed ID: 31863723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mass spectrometry based protein biomarkers and drug target discovery and clinical diagnosis in Age-Related progressing neurodegenerative diseases.
    Agrawal I; Tripathi P; Biswas S
    Drug Metab Rev; 2022 Feb; 54(1):22-36. PubMed ID: 35038284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protein Post-Translational Modification Crosstalk in Acute Myeloid Leukemia Calls for Action.
    Hernandez-Valladares M; Wangen R; Berven FS; Guldbrandsen A
    Curr Med Chem; 2019; 26(28):5317-5337. PubMed ID: 31241430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebrospinal Fluid and Plasma Biomarkers in Neurodegenerative Diseases.
    Seino Y; Nakamura T; Kawarabayashi T; Hirohata M; Narita S; Wakasaya Y; Kaito K; Ueda T; Harigaya Y; Shoji M
    J Alzheimers Dis; 2019; 68(1):395-404. PubMed ID: 30814356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mass Spectrometry Analysis of Lysine Posttranslational Modifications of Tau Protein from Alzheimer's Disease Brain.
    Thomas SN; Yang AJ
    Methods Mol Biol; 2017; 1523():161-177. PubMed ID: 27975250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dissecting Alzheimer's Disease Molecular Substrates by Proteomics and Discovery of Novel Post-translational Modifications.
    Deolankar SC; Patil AH; Koyangana SG; Subbannayya Y; Prasad TSK; Modi PK
    OMICS; 2019 Jul; 23(7):350-361. PubMed ID: 31225774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mass spectrometry-based proteomics analyses of post-translational modifications and proteoforms in human pituitary adenomas.
    Li J; Zhan X
    Biochim Biophys Acta Proteins Proteom; 2021 Mar; 1869(3):140584. PubMed ID: 33321259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Analysis of contribution of protein phosphorylation in the development of the diseases].
    Zavialova MG; Zgoda VG; Nikolaev EN
    Biomed Khim; 2017 Mar; 63(2):101-114. PubMed ID: 28414281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein glycosylation and glycoinformatics for novel biomarker discovery in neurodegenerative diseases.
    Costa J; Hayes C; Lisacek F
    Ageing Res Rev; 2023 Aug; 89():101991. PubMed ID: 37348818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Proteomics and Neurodegenerative Disorders: Advancements in the Diagnostic Analysis.
    Puranik N; Yadav D; Yadav SK; Chavda VK; Jin JO
    Curr Protein Pept Sci; 2020; 21(12):1174-1183. PubMed ID: 32392110
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glycoproteins as diagnostic and prognostic biomarkers for neurodegenerative diseases: A glycoproteomic approach.
    Xu MM; Zhou MT; Li SW; Zhen XC; Yang S
    J Neurosci Res; 2021 May; 99(5):1308-1324. PubMed ID: 33634546
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Methods Employed in Mass Spectrometric Analysis of Posttranslational Modifications (PTMs) and Protein-Protein Interactions (PPIs).
    Yakubu RR; Nieves E; Weiss LM
    Adv Exp Med Biol; 2019; 1140():169-198. PubMed ID: 31347048
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-translational quantitation by SRM/MRM: applications in cardiology.
    Gianazza E; Banfi C
    Expert Rev Proteomics; 2018 Jun; 15(6):477-502. PubMed ID: 29865883
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mapping Post-Translational Modifications in Brain Regions in Alzheimer's Disease Using Proteomics Data Mining.
    Deolankar SC; Patil AH; Rex DAB; Subba P; Mahadevan A; Prasad TSK
    OMICS; 2021 Aug; 25(8):525-536. PubMed ID: 34255573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.